1887

Abstract

Proliferative responses to human papillomavirus type 16 (HPV-16) E5 peptides were determined for short-term cell lines derived from peripheral blood mononuclear cells of 75 women. Cell lines from 16 of the 75 women proliferated in response to stimulation with pooled E5 peptides; this was most common for patients with low-grade squamous cervical intraepithelial lesions (LSIL; 6 of 15 patients, 40%) and less frequent for asymptomatic women with no cervical lesions (4 of 20, 20%), those with high-grade squamous intraepithelial lesions (HSIL; 5 of 33,15%) and others with cervical cancer (1 of 7, 14%, = 0·027). Amongst these patients, proliferative responses were exclusive to those that were positive for HPV-16 DNA(12 of 41, 29%; c.f. none of 13 HPV-16 DNA-negative subjects exhibited a proliferative response; =0·023) and were again most prevalent amongst HPV-16 DNA-positive LSIL (6 of 14, 43%), as compared with HPV-16 DNA-positive HSIL (5 of 23, 22%) or HPV-16 DNA-positive cervical cancer patients (1 of 4, 25%, > 0·05). In contrast, for asymptomatic women, responsiveness was statistically independent of HPV-16 DNA status, i.e. responsiveness in HPV-16 DNA-positive and DNAnegative subjects was observed in 3 of 15 (20%) and 1 of 5 (20%) cases, respectively ( > 0·05). There were no associations between detection of HPV-16 mRNA and proliferative responses ( > 0·05). These data suggest that HPV-16 E5-specific T-helper activity is depressed amongst women with HSIL lesions.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-79-8-1971
1998-08-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/79/8/9714245.html?itemId=/content/journal/jgv/10.1099/0022-1317-79-8-1971&mimeType=html&fmt=ahah

References

  1. Bavin P., Giles J. A., Deery A., Crow P., Griffiths P., Emery V. C., Walker P. 1993; Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high-grade cervical disease in a population presenting with a mildly dyskaryotic smear report. British Journal of Cancer 67:602–605
    [Google Scholar]
  2. Benton C., Shahidullah H., Hunter J. A. A. 1992; Human papillomavirus in the immunosuppressed. Papillomavirus Report 3:23–26
    [Google Scholar]
  3. Biswas C., Kell B., Mant C., Jewers R. J., Cason J., Muir P., Raju K. S., Best J. M. 1997; Detection of human papillomavirus type 16 early gene transcription by reverse transcription-PCR is associated with abnormal cervical cytology. Journal of Clinical Microbiology 35:1560–1564
    [Google Scholar]
  4. Borysiewicz L. K., Fiander A., Nimako M., Man S., Wilkinson G. W. G., Westmoreland D., Evans A. S., Adams M., Stacey S. N., Boursnell M. E. G., Rutherford E., Hickling J. K., Inglis S. C. 1996; A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical carcinoma. Lancet 347:1523–1527
    [Google Scholar]
  5. Cason J. 1996; Perinatal acquisition of cervical cancer associated human papillomaviruses. British Journal of Obstetrics & Gynaecology 103:853–858
    [Google Scholar]
  6. Cason J., Patel D., Naylor J., Lunney D., Shepherd P. S., Best J. M., McCance D. J. 1989; Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes. Journal of General Virology 70:2973–2987
    [Google Scholar]
  7. Cavuslu S., Starkey W. G., Kaye J. N., Biswas C., Mant C., Kell B., Rice P., Best J. M., Cason J. 1996; Detection of human papillomavirus type-16 (HPV-16) DNA utilizing microtitre-plate based amplification reactions and a solid-phase enzyme- immunoassay detection system. Journal of Virological Methods 58:59–69
    [Google Scholar]
  8. Cavuslu S., Goodlad J., Hobbs C., Connor A. M., Raju K. S., Best J. M., Cason J. 1997; Relationship between human papillomavirus infection and over-expression of p53 protein in cervical carcinomas and lymph-node metastases. Journal of Medical Virology 53:111–117
    [Google Scholar]
  9. Coleman N., Birley H. D., Renton A. M., Hanna N. F., Ryait B. K., Byrne M., Taylor-Robinson D., Stanley M. A. 1994; Immunological events in regressing genital warts. American Journal of Clinical Pathology 102:768–774
    [Google Scholar]
  10. Cusick J., Terry G., Ho L., Hollingworth T., Anderson M. 1992; Human papillomavirus type 16 DNA in cervical smears as a predictor of high-grade cervical intra-epithelial neoplasia. Lancet 339:959–960
    [Google Scholar]
  11. Denzoit F., Lang R. 1986; Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods 89:271–277
    [Google Scholar]
  12. de Villiers E.-M. 1992; Laboratory techniques in the investigation of human papillomavirus infection. Genitourinary Medicine 68:50–54
    [Google Scholar]
  13. Frazer I. H., Tindle R. W. 1992; Cell-mediated immunity to papillomaviruses. Papillomavirus Report 3:53–58
    [Google Scholar]
  14. Goldstein J. L., Brown M. S., Anderson R. G. W., Russell D. W., Schneide W. J. 1985; Receptor-mediated endocytosis : concepts emerging from the LDL receptor system. Annual Review of Cellular Biology 1:1–39
    [Google Scholar]
  15. Halbert C. L., Galloway D. A. 1988; Identification of the E5 open reading frame of human papillomavirus type 16. Journal of Virology 62:1071–1075
    [Google Scholar]
  16. Kell B., Jewers R. J., Cason J., Pakarian F., Kaye J. N., Best J. M. 1994; Detection of E5 oncoprotein in human papillomavirus type-16 positive cervical scrapes using antibodies raised to synthetic peptides. Journal of General Virology 75:2451–2456
    [Google Scholar]
  17. IARC 1995; Epidemiology of infection. In Monographs on the Evaluation of Carcinogenic Risks to Humans, Human Papillomaviruses pp. 60–65 Lyon: International Agency for Research on Cancer, World Health Organization;
    [Google Scholar]
  18. Luxton J. C., Rose R. C., Coletart T., Wilson P., Shepherd P. S. 1997; Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls. Journal of General Virology 78:917–923
    [Google Scholar]
  19. Mant C., Kell B., Best J. M., Cason J. 1997; Polymerase chain reaction protocols for the detection of DNA from mucosal human papillomavirus types -6,-11, -16, -18, -31 and -33. Journal of Virological Methods 66:169–178
    [Google Scholar]
  20. Oelze I., Kartenbeck J., Crusius K., Alonso A. 1995; Human papillomavirus type 16 affects cell-cell communication in an epithelial cell line. Journal of Virology 69:4489–4494
    [Google Scholar]
  21. Seedorf K., Krammer G., Durst M., Suhai S., Rowekamp W. G. 1985; Human papillomavirus type 16 DNA sequence. Virology 145:181–185
    [Google Scholar]
  22. Shepherd P. S., Rowe A. J., Cridland J. C., Coletart T., Wilson P., Luxton J. C. 1996; Proliferative T-cell responses to human papillomavirus type 16 peptides in patients with cervical dysplasia. Journal of General Virology 77:593–602
    [Google Scholar]
  23. Stoler M., Rhodes C., Whitbeck A., Wolinsky S., Chow L., Broker T. 1992; Human papillomavirus type 16 gene expression in cervical neoplasias. Human Pathology 23:117–128
    [Google Scholar]
  24. Tsukui T., Hildesheim A., Schiffman M. H., Lucci J. III Contois D., Lawler P., Rush B. B., Lorincz A. T., Corrigan A., Burk R. D., Qu W., Marshall M. A., Mann D., Carrington M., Clerici M., Shearer G. M., Carbone D. P., Scott D. R., Houghten R. A., Berzofsky J. A. 1996; Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides : correlation with cervical pathology. Cancer Research 56:3967–3974
    [Google Scholar]
  25. zur Hausen H. 1994; Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Current Topics in Microbiology and Immunology 186:131–156
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-79-8-1971
Loading
/content/journal/jgv/10.1099/0022-1317-79-8-1971
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error